UroAlert - GU Oncology Weekly

April 02, 2026

Videos

Peer-to-Peer Clinical Conversations

Counseling Women with Bladder Cancer: Balancing Treatment Goals and Quality of Life - Sarah Psutka

Sarah Psutka speaks with Tian Zhang about caring for women with bladder cancer.

Co-PSMA Trial Explores Tracer for Detecting Recurrence After Radical Prostatectomy - Louise Emmett

Louise Emmett

Louise Emmett discusses the Co-PSMA trial comparing gallium-68 PSMA PET with 64Cu-SAR-bisPSMA in biochemically recurrent prostate cancer post-prostatectomy.

Beyond the Abstracts

Intraoperative Skills for Transurethral Resection of Bladder Tumor: Objective Assessment and Construct Validity of the ENTRY Metrics - Beyond the Abstract

Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use - Beyond the Abstract

Conference Coverage

PSMA and Beyond 2026: Scaling Operations in Theranostics Clinical Research - Integrating Teams, Processes, and Regulatory Strategy

PSMA and Beyond 2026: Review of Phase 1/2 Compounds Recently Published

SES AUA 2026: Treatment of UTUC with UGN-101: Baseline Characteristics from the uTRACT Registry Study for UGN-101

EAU 2026: Impact of Girentuximab Based Radionuclide Imaging in Patients with RCC on Virtual Tumor Board Decision Making: An Interim Analysis

ASCO GU 2026: Avelumab in Combination with Other Anticancer Agents as 1L Maintenance Treatment of Advanced UC: Primary Analysis from the JAVELIN Bladder Medley Phase 2 Trial

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.

Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.

AI-assessed sarcopenia as an independent predictor of neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer.

Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment.

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

Is complete TURBT mandatory before radical cystectomy in cases of muscle-invasive bladder cancer?

Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer.

Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.

Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.

Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer.

FLASH radiotherapy enables dose escalation and improves survival in an orthotopic muscle-invasive bladder cancer mouse model.

Evolving patterns of bladder cancer mortality in US adults: a two-decade analysis reveals persistent disparities despite overall progress (1999-2020).

Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response.

De-Intensification Strategies in Non-Muscle-Invasive Bladder Cancer: Outcomes and Cost Impact of In-Office Bladder Fulguration.

Penile & Urethral Cancers

Strategies for prevention, early detection and management of penile and testicular cancer in primary healthcare: scoping review protocol.

Penile Cancer-A Preventable Cause of Death in Elderly Men.

Prognostic Factors of Survival in Patients with Surgically Treated Penile Squamous Cell Carcinoma: A Retrospective Cohort Analysis.

The identification of clinicopathological features predictive of recurrence following lymphadenectomy in penile cancer: A systematic review.

Efficacy and Safety of Immune Checkpoint Blockade in Locally Advanced or Metastatic Penile Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

The Role of the Tumor Microenvironment in Penile Carcinoma and Emerging Therapeutic Concepts: A Review - Beyond the Abstract

Renal Cancer

Partitioned Overall Survival: Comprehensive Analysis of Survival States over 4 Years in CheckMate 9ER Comparing First-Line Nivolumab plus Cabozantinib versus Sunitinib in Advanced Renal Cell Carcinoma - Beyond the Abstract

Application of adaptive deep learning-based automatic segmentation in radiomics model for preoperative WHO/ISUP grading of clear cell renal cell carcinoma: a retrospective comparative study with manual segmentation.

Partial Nephrectomy of Renal Cell Carcinoma in Horseshoe Kidney with Assistance of Intraoperative Retrograde Pyelogram: A Case Report and Literature Review.

Hidden in Plain Sight: Metastatic Renal Cell Carcinoma Masquerading as Multinodular Thyroid Disease.

Cardiac Biomarkers in Patients With Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.

Adjunctive Techniques for Optimizing Percutaneous CT-Guided Cryoablation of Renal Tumours.

Cancer-Specific Mortality in Sarcomatoid Renal Cell Carcinoma: A Histological Subtype-Controlled Analysis.

A Mitochondrial Plasma Proteomic Signature Identifies Metastatic Chromophobe Renal Cell Carcinoma.

Beyond clear cell: Rare histologic and molecular variants of renal cell carcinoma.

Enucleation versus enucleoresection in robotic partial nephrectomy: Real-world data from the multicenter YAU kidney cancer database.

Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.

Genome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer.

Prostate Cancer

Prostate Cancer Foundation and Hästens Launch Global Health Award to Expand Prostate Cancer Care in Emerging Countries

Evaluating the Continuity of Telehealth Usage Among Hispanics: The Impact of Language Barriers.

Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Localised Prostate Cancer (HYPO-RT-PC): 10-Year Outcomes of an Open-Label, Randomised, Phase 3, Non-Inferiority Trial - Beyond the Abstract

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer.

Imaging Features That Predict Indeterminate Bone Lesion Outcomes on 18F-DCFPyL PSMA PET/CT Scan: A Multicenter Cohort of 42 Biopsy-Proven Lesions.

Implementation of a Telehealth-Based Rapid Access Program for the Evaluation of Men Referred for Elevated PSA.

AURKA inhibitor VIC-1911 induces mitotic defects and functional BRCAness, sensitizing prostate cancer to PARP inhibition.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Early detection of prostate cancer-recommendations of the updated S3 guideline 2025.

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.

PD-1/PD-L1 for prostate cancer: from clinical trials to practice.

Number of risk factors versus infection after transrectal prostate biopsy: a nationwide population-based study.

Association of Natural Disasters on Trends of County-Level Prostate-Specific Antigen (PSA) Screening.

Conventional vs. Hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT.

From complexity to clarity: GPT-4 for patient-centered prostate cancer pathology reports.

Same-day fluorescence confocal microscopy of MRI-targeted prostate biopsies: A feasibility study.

Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.

Integrated Urinary and Tissue Proteomic Signatures Reveal Core and Progression Biomarkers in MRI-Visible and MRI-Non-Visible Prostate Cancer.

Predicting 1-Year Trifecta Outcomes After High-Intensity Focused Ultrasound and Cryoablation for Low- and Intermediate-Risk Prostate Cancer.

Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.

Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).

Disparities in Outcomes in Latino Subpopulations with Localized Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Analysis.

Differential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design.

Nerve-Sparing in High-Risk Prostate Cancer: Advantages and Pitfalls of Current Strategies and Technologies.

Quality and Usability of Prostate Cancer Information Generated by Artificial Intelligence Chatbots: A Comparative Analysis.

Hypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer.

Prognostic Value of Cycle 1 SPECT SUVmean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617.

Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.

Timing and Resolution of Bothersome Hot Flashes Following Short Course Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix, and Stereotactic Body Radiotherapy for Localized Prostate Cancer.

Antibody-drug conjugates in prostate cancer: current landscape and future directions.

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer.

Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis.

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer.

Association Between Baseline Prostate MRI PI-RADS Classification and Risk of Gleason Upgrade During Active Surveillance: A Systematic Review and Meta-Analysis - Beyond the Abstract

Upper Tract Tumors

Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability.

Radiosurgery in Upper Tract Urothelial Carcinoma (UTUC).

Diagnostic dilemmas for upper-tract urothelial carcinoma (UTUC)-grade discordance between endoscopic biopsy and final surgical pathology.

Testicular Cancer

Inflammatory and Nested Testicular Sex Cord Tumors: Clinical and Molecular Characterization.

Review of the effect of atrazine on the HPG axes and steroidogenic pathways in males: relevance for testicular and prostate cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC